+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Axial Spondyloarthritis Market - Global Forecast 2026-2032- Product Image
Axial Spondyloarthritis Market - Global Forecast 2026-2032- Product Image
New

Axial Spondyloarthritis Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5924702
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The axial spondyloarthritis market is undergoing rapid transformation, propelled by significant advancements in clinical innovation, care delivery models, and policy frameworks. Forward-thinking senior leaders need clear insights to confidently navigate operational, regulatory, and commercial complexity in the evolving B2B healthcare environment.

Axial Spondyloarthritis Market Snapshot: Growth Trajectory and Commercial Outlook

The axial spondyloarthritis market demonstrates a robust expansion, driven by advances in targeted therapies and the strategic realignment of clinical priorities. In recent years, the market increased from USD 723.14 million in 2025 to USD 961.80 million in 2026, with an anticipated CAGR of 33.27%. Projections place market value at USD 5.40 billion by 2032. This trajectory reflects increased disease awareness, greater uptake of innovative treatments, and expanding payer confidence in advanced therapies for inflammatory and chronic musculoskeletal conditions.

Scope & Segmentation: Structural Overview and Strategic Relevance

This report delivers comprehensive segmentation of the axial spondyloarthritis market, providing clarity on commercial opportunities and guiding operational decisions for stakeholders seeking to strengthen their competitive position.

  • Therapeutic Product Classes: Conventional disease-modifying antirheumatic drugs (DMARDs), IL-17 inhibitors, JAK inhibitors, NSAIDs, and TNF inhibitors, each shaping treatment protocols and influencing uptake across clinical pathways.
  • Treatment Lines: First-line symptom management, as well as second- and third-line strategies, designed around mechanistic differentiation and previous therapy exposure, facilitating tailored patient approaches and supporting managed care decisions.
  • Distribution Channels: Hospital pharmacies for infused and complex therapies, retail locations for oral and self-injectable products, and online or remote pharmacy services enabling chronic and home-based treatments—all crucial to ensure uninterrupted therapy access.
  • Routes of Administration: Injectable, intravenous, and oral delivery formats, each contributing to patient adherence, clinical safety, and real-world outcomes, requiring robust monitoring and flexible administration settings.
  • End User Settings: Hospitals, specialty clinics, and home-care environments, shaping utilization trends and determining reimbursement interactions for stakeholders targeting different patient populations.
  • Geographies Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific, with analysis of regional healthcare structures, reimbursement landscapes, and unique demographic drivers to support precise localization strategies.

Key Takeaways: Strategic Insights for Stakeholders

  • Clinical heterogeneity and increasingly complex disease presentations are prompting the development of more nuanced diagnostic frameworks, leading to dynamic guideline revisions and multi-disciplinary care coordination.
  • Industry incentives are evolving, with adoption of targeted therapies compelling manufacturers to expand evidence-generation initiatives and pursue value-based contracts to maintain competitiveness in mature and emerging markets.
  • Rapid integration of digital health and telemedicine is enhancing patient monitoring, adherence, and real-world data collection for both urban and remote populations, ensuring broader access and improved outcomes.
  • Growing influence of real-world evidence on payer decisions encourages investment in trial designs that combine clinical efficacy results with quality-of-life and functional outcome measures.
  • Commercialization models are adapting, emphasizing robust product lifecycle management, formation of strategic alliances, and proactive intellectual property planning to optimize long-term market presence.

Tariff Impact: Adjustments Affecting Supply and Access

Recent United States tariff changes, set for 2025, introduce new operational complexities that affect continuity across the axial spondyloarthritis supply chain. Manufacturers must reassess sourcing strategies for both active ingredients and finished products, build contingency inventory, and explore regional manufacturing partnerships to address cost and supply uncertainties. Payer and hospital procurement teams are actively reviewing formulary placements and supplier relationships to manage potential disruptions. Scenario planning at multiple organizational levels is essential to mitigate tariff risks and sustain patient access through evolving global trade conditions.

Methodology & Data Sources

This research integrates structured interviews with clinicians, payers, procurement leads, and patient advocates. Analysis is supported by data from clinical trial registries, regulatory filings, and peer-reviewed publications, with robust real-world registry and cohort data ensuring actionable insights for commercial and clinical agendas.

Why This Report Matters

  • Empowers senior decision-makers to anticipate industry shifts, adapt commercialization strategies rapidly, and align operational models with stakeholder priorities.
  • Provides evidence-based recommendations for building payer and supplier trust, improving supply chain agility, and identifying new opportunities within distribution and care segmentations.

Conclusion

The axial spondyloarthritis market remains defined by its scientific evolution and regulatory progression. Leaders who align clinical innovation with evidence-driven market access strategies will be best equipped to ensure sustainable success as complexity grows and new opportunities arise.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Axial Spondyloarthritis Market, by Product Class
8.1. Conventional DMARDs
8.2. IL-17 Inhibitors
8.3. JAK Inhibitors
8.4. NSAIDs
8.5. TNF Inhibitors
9. Axial Spondyloarthritis Market, by Treatment Line
9.1. First Line
9.2. Second Line
9.3. Third Line
10. Axial Spondyloarthritis Market, by Route Of Administration
10.1. Injectable
10.2. Intravenous
10.3. Oral
11. Axial Spondyloarthritis Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Axial Spondyloarthritis Market, by End User
12.1. Home Care
12.2. Hospitals
12.3. Specialty Clinics
13. Axial Spondyloarthritis Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Axial Spondyloarthritis Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Axial Spondyloarthritis Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Axial Spondyloarthritis Market
17. China Axial Spondyloarthritis Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Acelyrin, Inc.
18.7. Amgen Inc.
18.8. AstraZeneca plc
18.9. Biogen Inc.
18.10. Boehringer Ingelheim International GmbH
18.11. Bristol-Myers Squibb Company
18.12. Eli Lilly and Company
18.13. Gilead Sciences, Inc.
18.14. Janssen Biotech, Inc.
18.15. Kyowa Kirin Co., Ltd.
18.16. Merck & Co., Inc.
18.17. Novartis AG
18.18. Panacea Biotec Ltd.
18.19. Pfizer Inc.
18.20. Regeneron Pharmaceuticals, Inc.
18.21. Sandoz International GmbH
18.22. Sanofi S.A.
18.23. Sun Pharmaceutical Industries Ltd.
18.24. Takeda Pharmaceutical Company Limited
18.25. Teva Pharmaceutical Industries Ltd.
18.26. UCB S.A.
18.27. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 85. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 86. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 97. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 98. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 110. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 111. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 116. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 117. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 128. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 129. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 134. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 135. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 140. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 141. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 148. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 152. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
TABLE 153. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 154. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Axial Spondyloarthritis market report include:
  • AbbVie Inc.
  • Acelyrin, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 961.8 Million
Forecasted Market Value ( USD ) by 2032 $ 5400 Million
Compound Annual Growth Rate33.2%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Medications for Non-Radiographic Axial Spondyloarthritis Market - Global Forecast 2025-2030 - Product Image

Medications for Non-Radiographic Axial Spondyloarthritis Market - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Axial Spondyloarthritis (axSpA) Epidemiology Forecast 2025-2034 - Product Image

Axial Spondyloarthritis (axSpA) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Axial Spondyloarthritis (Axspa) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Axial Spondyloarthritis (Axspa) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025 - Product Image

Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2025 - Product Image

Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Axial Spondyloarthritis Drug Market

Axial Spondyloarthritis (axSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints. It is a chronic, progressive condition that can cause pain, stiffness, and swelling in the affected areas. Immune Disorders Drugs are used to treat axSpA, as they help to reduce inflammation and pain. These drugs can be taken orally, injected, or infused, depending on the severity of the condition. Commonly used drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. The Axial Spondyloarthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of axSpA, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.